SHANDONG SINOBIOWAY BIOMEDICINE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.61 CNY | -1.52% |
|
-1.38% | -6.78% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 357M 49.42M | Sales 2023 | 430M 59.48M | Capitalization | 9.63B 1.33B |
|---|---|---|---|---|---|
| Net income 2022 | -14M -1.94M | Net income 2023 | -332M -45.95M | EV / Sales 2022 | 29 x |
| Net cash position 2022 | 18.45M 2.55M | Net cash position 2023 * | - 0 | EV / Sales 2023 | 22.4 x |
| P/E ratio 2022 |
-706
x | P/E ratio 2023 |
-29
x | Employees | 666 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 58.78% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.52% | ||
| 1 week | -1.38% | ||
| Current month | -1.38% | ||
| 1 month | +5.50% | ||
| 3 months | +19.60% | ||
| 6 months | -21.19% | ||
| Current year | -6.78% |
1 week
13.56
14.00
1 month
12.1314.17
Current year
8.5414.81
1 year
8.5421.69
3 years
8.5425.68
5 years
5.5034.10
10 years
5.5042.49
| Managers | Title | Age | Since |
|---|---|---|---|
JiaLin Yue
CEO | Chief Executive Officer | 56 | 22-07-08 |
Yang Jun Liu
DFI | Director of Finance/CFO | 49 | 22-07-08 |
Hui Zhao
BRD | Director/Board Member | 55 | 22-04-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ai Hua Pan
CHM | Chairman | 66 | 15-12-14 |
Xue Ming Yan
BRD | Director/Board Member | 51 | 15-10-12 |
Wen Jun Liu
BRD | Director/Board Member | 41 | 22-07-08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.45% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 13.61 | -1.52% | 5,730,200 |
| 24-05-07 | 13.82 | +0.73% | 4,156,541 |
| 24-05-06 | 13.72 | -0.58% | 7,499,907 |
| 24-04-30 | 13.8 | -0.50% | 10,090,240 |
End-of-day quote Shenzhen S.E., May 07, 2024
More quotes
Shandong Sinobioway Biomedicine Co Ltd, formerly Zibo Wanchang Science & Technology Co Ltd, is a China-based company principally engaged in the manufacturing of pharmaceuticals. The Company is engaged in the business of interferon, nerve growth factor, biopharmaceutical contract research organization (CRO)/pharmaceutical contract development and manufacturing enterprise (CDMO), vaccines and pharmaceutical intermediates. The Company's main products include anferon, encyclopedia, Corona Virus Disease2019 vaccine and others. The Company distributes its products within domestic market.
Sector
Pharmaceuticals
Calendar
2024-05-22
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -6.78% | 1.26B | |
| -3.59% | 89.33B | |
| +4.08% | 41.19B | |
| -15.09% | 31.87B | |
| +53.68% | 24.52B | |
| -15.13% | 15.68B | |
| -8.63% | 12.34B | |
| -40.39% | 12.23B | |
| +6.22% | 8.83B | |
| -6.20% | 8.28B |
- Stock Market
- Equities
- 002581 Stock